GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in two phase III …
After withdrawal, GSK touts another Blenrep combo win as …
WEBMar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · The combination of Blenrep with Takeda’s Velcade and the steroid dexamethasone (Vd) significantly cut the risk of progression or death by 59% compared with Johnson & Johnson’s Darzalex and Vd in...
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBGlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
WEBFeb 5, 2024 · GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma.
GSK backs up its Blenrep rehab bid with survival data
WEBFeb 7, 2024 · GSK has reported data it hopes will allow a return to the US for Blenrep, the first BCMA-targeting drug to launch for multiple myeloma.
Blenrep combination reduced the risk of disease progression or …
WEBJun 2, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory ...
DREAMM-8 Phase III Trial for Blenrep | Int'l Myeloma Foundation
WEBMar 7, 2024 · GSK press releases reports on positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma.
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBNov 27, 2023 · GSK Announces Positive Results in a Phase III Trial of Blenrep. On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma.
FDA approves GSK's Blenrep for advanced multiple myeloma
WEBSep 15, 2024 · The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.
Skip to content